Skip to main content

Advertisement

SpringerLink
Log in

A pharmacogically guided phase I study of carboplatin in combination with methotrexate and vinblastine in advanced urothelial cancer

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Carboplatin is an alternative for cisplatin in the treatment of urothelial cancers. A pharmacologically guided phase I study of carboplatin in combination with methotrexate (30 mg/m2) and vinblastine (4 mg/m2) was conducted in ten patients by increment of the area under the plasma concentration versus time curve (AUC) for ultrafilterable carboplatin using the Calvert formula. The maximal tolerated AUC was 5 mg ml−1 min, with neutropenia being the dose-limiting toxicity. There was a significant linear correlation between the percentage of decrease in neutrophil count and the carboplatin AUC. Determination of the glomerular filtration rate by the isotopic method allowed us to adapt the dose of carboplatin given to patients suffering from urothelial cancer, who frequently have impaired renal function. The recommended AUC for phase II study is 4 mgml−1 min.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bellmunt J, Albaneil J, Gallego S, Ribas A, Vincente P, Carulla J, De Torres J, Morote J, Lopez M, Solé LA (1992) Carboplatin, methotrexate, and vinblastine in patients with bladder cancer who were ineligible for cisplatin-based chemotherapy. Cancer 70:1974

    Article  PubMed  CAS  Google Scholar 

  2. Calvert AH, Newell DR, Gumbrell LA, O’Reilly S, Burneil M, Boxall FE, Siddick ZH, Judson IR, Gore ME, Wiltshaw E (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748

    PubMed  CAS  Google Scholar 

  3. Chantler C, Garnett ES, Parsons V, Veall N (1969) Glomerular filtration rate measurement in man by single injection method using 51Cr-EDTA. Clin Sci 37:169

    PubMed  CAS  Google Scholar 

  4. Cockroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16: 31

    Article  Google Scholar 

  5. Egorin MJ, Van Echo DA, Tipping SJ, Olman EA, Whitacre MY, Thompson BW, Aisner J (1984) Pharmacokinetics and dosage reduction of cis-diammine(l,l-cyclobutane dicarboxylo)-platinum in patients with impaired renal function. Cancer Res 44: 5432

    PubMed  CAS  Google Scholar 

  6. Egorin MJ, Van Echo DA, Olman EA, Whitacre MY, Forrest A, Aisner J (1985) Prospective validation of a pharmacologically based dosing scheme for cis-diamminedichloroplatinum(II) analogue diamminecyclobutane dicarboxylatoplatinum. Cancer Res 45:6502

    PubMed  CAS  Google Scholar 

  7. Eisenberger M, Hornedo J, Silva H, Donehower R, Splaulding M, Van Echo D (1986) Carboplatin (NSC-241-240): an active platinum analog for the treatment of squamous-cell carcinoma of the head and neck. J Clin Oncol 4:1506

    PubMed  CAS  Google Scholar 

  8. Hande KR (1993) Pharmacologic-based dosing of carboplatin: a better method. J Clin Oncol 11:2295

    PubMed  CAS  Google Scholar 

  9. Harker WG, Meyers FJ, Freiha FS, Palmer JM, Shortliffe LD, Hannigan JF, McWhirter KM, Torti FM (1991) An effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract: a Northern California Oncology Group study. J Clin Oncol 3:1463

    Google Scholar 

  10. Imbert AM, Pignon T, Lena N (1983) Methotrexate enzymatic assay with the use of centrifugal analyser Cobas-bio. Clin Chim Acta 29:1665

    Google Scholar 

  11. Klocker J, Pont J, Schumor J, Prüger J, Kienzer H (1991) Carboplatin, methotrexate and vinblastine (Carbo-MV) for advanced urothelial cancer: a phase II trial. Am J Clin Oncol 14:328

    Article  PubMed  CAS  Google Scholar 

  12. LeRoy AF, Wehling ML, Sponseller HL, Friauf WS, Solomon RE, Dedrick RL (1977). Analysis of platinum in biological materials by flameless atomic absorption spectrophotometry. Biochem Med 18:184

    Article  PubMed  CAS  Google Scholar 

  13. Lorusso V, Catino A, Leone B, Rabinovich M, Gargano G, Paradiso A, De Lena M (1993) Carboplatin plus ifosfamide as salvage treatment of epithelial ovarian cancer: a pilot study. J Clin Oncol 11: 1952

    PubMed  CAS  Google Scholar 

  14. Medical Research Council Working Party on Urological Cancer, Subgroup in Advanced Bladder Cancer (1987) A phase II study of carboplatin in metastatic transitional cell carcinoma of the bladder. Eur J Cancer Clin Oncol 23:375

    Article  Google Scholar 

  15. Reyno LM, Egorin MJ, Canetta RM, Jodrell DI, Swenerton KD, Pater JL, Burroughs JN, Novak MJ, Sridhara R (1993) Impact of cyclophosphamide on relationships between carboplatin exposure and response or toxicity when used in the treatment of advanced ovarian cancer. J Clin Oncol 11:1156

    PubMed  CAS  Google Scholar 

  16. Smith IE, Evans BD, Gore ME, Vincent MD, Repetto L, Yarnold JR, Ford HT (1987) Carboplatin (Paraplatin; JM8) and etoposide (VP16) as first-line combination therapy for small-cell lung cancer. J Clin Oncol 5:185

    PubMed  CAS  Google Scholar 

  17. Sorensen BT, Strömgren A, Jakobsen P, Jakobsen A (1991) Dose-toxicity relationship of carboplatin in combination with cyclophosphamide in ovarian cancer patients. Cancer Chemother Pharmacol 28:337

    Article  Google Scholar 

  18. Sorensen BT, Strömgren A, Jakobsen P, Jakobsen A (1993) Is creatinine clearance a sufficient measurement for GFR in carboplatin dose calculation (abstract 595)? Proceedings, ECCO 7 Meeting, Jerusalem November 14–18

  19. Van der Vijgh WJF (1991) Clinical pharmacokinetics of carboplatin. Clin Pharmacokinet 21:242

    Article  PubMed  Google Scholar 

  20. Wagstaff AJ, Ward A, Benfield P, Heel RC (1989) Carboplatin: a preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of cancer. Drugs 37:162

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Groupe de Pharmacologie Clinique et Expérimentale des Médicaments Anticancéreux, Centre Claudius Regaud, 20 rue du Pont-St.-Pierre, F-31052, Toulouse, France

    Etienne Chatelut, Christine Chevreau, Valérie Brunner, Mathilde Martinez, Roland Bugat & Pierre Canal

  2. Université Paul Sabatier, Toulouse, France

    Etienne Chatelut, Georges Houin & Roland Bugat

Authors
  1. Etienne Chatelut
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christine Chevreau
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Valérie Brunner
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mathilde Martinez
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Georges Houin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Roland Bugat
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Pierre Canal
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chatelut, E., Chevreau, C., Brunner, V. et al. A pharmacogically guided phase I study of carboplatin in combination with methotrexate and vinblastine in advanced urothelial cancer. Cancer Chemother. Pharmacol. 35, 391–396 (1995). https://doi.org/10.1007/s002800050252

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s002800050252

Key words

Search

Navigation